274 related articles for article (PubMed ID: 33706221)
41. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
Müller S; Menciotti G; Borgarelli M
J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
[TBL] [Abstract][Full Text] [Related]
42. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
Sabetti MC; Fidanzio F; Troìa R; Perissinotto L; Romito G; Mazzoldi C; Quintavalla C; Crosara S; Dondi F
J Vet Cardiol; 2022 Jun; 41():57-69. PubMed ID: 35245876
[TBL] [Abstract][Full Text] [Related]
43. Severity of myxomatous mitral valve disease in dogs may be predicted using neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio.
Ku D; Chae Y; Kim C; Koo Y; Lee D; Yun T; Chang D; Kang BT; Yang MP; Kim H
Am J Vet Res; 2023 Jun; 84(6):. PubMed ID: 37024099
[TBL] [Abstract][Full Text] [Related]
44. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
Dickson D; Caivano D; Matos JN; Summerfield N; Rishniw M
J Vet Cardiol; 2017 Dec; 19(6):469-479. PubMed ID: 29111284
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease.
Baron Toaldo M; Romito G; Guglielmini C; Diana A; Pelle NG; Contiero B; Cipone M
J Vet Intern Med; 2018 May; 32(3):914-921. PubMed ID: 29572938
[TBL] [Abstract][Full Text] [Related]
46. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for coughing in dogs with naturally acquired myxomatous mitral valve disease.
Ferasin L; Crews L; Biller DS; Lamb KE; Borgarelli M
J Vet Intern Med; 2013; 27(2):286-92. PubMed ID: 23398050
[TBL] [Abstract][Full Text] [Related]
48. Prognostic relevance of left cardiac enlargement in dogs with preclinical myxomatous mitral valve disease.
Grosso G; Vezzosi T; Domenech O; Tognetti R
J Vet Cardiol; 2023 Feb; 45():50-58. PubMed ID: 36702085
[TBL] [Abstract][Full Text] [Related]
49. Association between echocardiographic indexes and urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in dogs with myxomatous mitral valve disease.
Crosara S; Fidanzio F; Oricco S; Dondi F; Mazzoldi C; Monari E; Romito G; Sabetti MC; Troìa R; Quintavalla C
Res Vet Sci; 2024 May; 171():105211. PubMed ID: 38458044
[TBL] [Abstract][Full Text] [Related]
50. Neutrophil-to-lymphocyte ratio is increased in dogs with acute congestive heart failure secondary to myxomatous mitral valve disease compared to both dogs with heart murmurs and healthy controls.
DeProspero DJ; Hess RS; Silverstein DC
J Am Vet Med Assoc; 2023 Nov; 261(11):1-8. PubMed ID: 37406992
[TBL] [Abstract][Full Text] [Related]
51. Left atrial volume and function in dogs with naturally occurring myxomatous mitral valve disease.
Höllmer M; Willesen JL; Tolver A; Koch J
J Vet Cardiol; 2017 Feb; 19(1):24-34. PubMed ID: 27825670
[TBL] [Abstract][Full Text] [Related]
52. Assessment of global and regional left ventricular volume and shape by real-time 3-dimensional echocardiography in dogs with myxomatous mitral valve disease.
Ljungvall I; Höglund K; Carnabuci C; Tidholm A; Häggström J
J Vet Intern Med; 2011; 25(5):1036-43. PubMed ID: 21848946
[TBL] [Abstract][Full Text] [Related]
53. Genetics of canine myxomatous mitral valve disease.
O'Brien MJ; Beijerink NJ; Wade CM
Anim Genet; 2021 Aug; 52(4):409-421. PubMed ID: 34028063
[TBL] [Abstract][Full Text] [Related]
54. Prediction of clinically important acquired cardiac disease without an echocardiogram in large breed dogs using a combination of clinical, radiographic and electrocardiographic variables.
Wesselowski S; Gordon SG; Meddaugh N; Saunders AB; Häggström J; Cusack K; Janacek BW; Matthews DJ
J Vet Cardiol; 2022 Apr; 40():126-141. PubMed ID: 34483077
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease.
Tidholm A; Höglund K; Häggström J; Ljungvall I
J Vet Intern Med; 2015; 29(6):1510-7. PubMed ID: 26365438
[TBL] [Abstract][Full Text] [Related]
56. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
Kim HJ; Kim J; Kim S; Kim HJ
BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
[TBL] [Abstract][Full Text] [Related]
57. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
[TBL] [Abstract][Full Text] [Related]
58. Comparison of different radiographic scores with associated echocardiographic measurements and prediction of heart enlargement in dogs with and without myxomatous mitral valve disease.
Levicar C; Granados-Soler JL; Freise F; Raue JF; Nolte I; Bach JP
J Vet Cardiol; 2022 Dec; 44():1-12. PubMed ID: 36174296
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of selected one-, two- and three-dimensional and Doppler echocardiographic methods to assess severity in dogs with myxomatous mitral valve disease.
Tidholm A; Häggström J
J Vet Cardiol; 2022 Feb; 39():89-101. PubMed ID: 35008002
[TBL] [Abstract][Full Text] [Related]
60. Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease.
Zois NE; Moesgaard SG; Kjelgaard-Hansen M; Rasmussen CE; Falk T; Fossing C; Häggström J; Pedersen HD; Olsen LH
Vet J; 2012 Apr; 192(1):106-11. PubMed ID: 21696985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
